Antimicrobial susceptibilities and treatment options for pediatric Mycoplasma pneumoniae infections - does macrolide resistance matter?

Current Pediatric Reviews

Volumn 9, Issue 4, 2013, Pages 279-288

  Waites, Ken B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Antibiotic resistance; Antimicrobial susceptibility; Macrolide; Mycoplasma pneumoniae; Treatment

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GEMIFLOXACIN; GLUCOCORTICOID; GLYCYLCYCLINE DERIVATIVE; IMMUNOGLOBULIN; KETOLIDE; LEVOFLOXACIN; LINCOMYCIN; MACROLIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; MINOCYCLINE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RNA 16S; RNA 23S; ROXITHROMYCIN; SOLITHROMYCIN; TELITHROMYCIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG;

ADHESIN P1 GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL GENE; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DNA SEQUENCE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOXICITY; EUROPE; FEVER; GENE MUTATION; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MYCOBACTERIUM AFRICANUM; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

EID: 84891510647     PISSN: 15733963     EISSN: 18756336     Source Type: Journal    
DOI: 10.2174/157339630904131223104312     Document Type: Article

References (54)

1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17(4): 697-728, table of contents.
2. CLSI. CLSI Document M43-P. Methods for Antimicrobial Susceptibility Testing of Human Mycoplasmas; Approved Guideline. Wayne, PA: Clinical and Laboratory Standards Institute 2011.
3. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009; 53(5): 2139-41.
4. Smilack JD, Burgin WW, Jr., Moore WL, Jr., Sanford JP. Mycoplasma pneumoniae pneumonia and clindamycin therapy. Failure to demonstrate efficacy. JAMA 1974; 228(6): 729-31.
5. Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004; 48(12): 4624-30.
6. Li X, Atkinson TP, Hagood J, et al. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009; 28(8): 693-6.
7. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 2008; 52(10): 3542-9.
8. Peuchant O, Menard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64(1): 52-8.
9. Dumke R, Schurwanz N, Lenz M, et al. Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach. J Clin Microbiol 2007; 45(8): 2726-30.
10. Lin C, Li S, Sun H, et al. Nested PCR-linked capillary electrophoresis and single-strand conformation polymorphisms for detection of macrolide-resistant Mycoplasma pneumoniae in Beijing, China. J Clin Microbiol 2010; 48(12): 4567-72.
11. Spuesens EB, Hoogenboezem T, Sluijter M, et al. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing. J Microbiol Methods 2010; 82(3): 214-22.
12. Bebear C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011; 6(4): 423-31.
13. Lucier TS, Heitzman K, Liu SK, Hu PC. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 1995; 39(12): 2770-3.
14. Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 2001; 45(8): 617-20.
15. Pereyre S, Guyot C, Renaudin H, et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother 2004; 48(2): 460-5.
16. Degrange S, Renaudin H, Charron A, et al. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother 2008; 61(6): 1390-2.
17. Gruson D, Pereyre S, Renaudin H, et al. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother 2005; 49(3): 1190-3.
18. Nitu Y, Hasegawa S, Kubota H. In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae. Antimicrob Agents Chemother 1974; 5(5): 513-9.
19. Stopler T, Gerichter CB, Branski D. Antibiotic-resistant mutants of Mycoplasma pneumoniae. Isr J Med Sci 1980; 16(3): 169-73.
20. Taylor-Robinson D, Webster AD, Furr PM, Asherson GL. Prolonged persistence of Mycoplasma pneumoniae in a patient with hypogammaglobulinaemia. J Infect 1980; 2(2): 171-5.
21. Bebear CM, Kempf I. Antimicrobials and antimicrobial resistance. In: Blanchard A, Browning G, eds. Mycoplasmas molecular biology pathogenicity and strategies for control. Norfolk, UK: Horizon Bioscience 2005.
22. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8(4): 214-21.
23. Xin D, Mi Z, Han X, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009; 53(5): 2158-9.
24. Zhao F, Lv M, Tao X, et al. Antibiotic Sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolideresistant isolates from Beijing, China. Antimicrob Agents Chemother 2012; 56(2):1108-9.
25. Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010; 67(4): 355-8.
26. Miyashita N, Oka M, Kawai Y, Yamaguchi T, Ouchi K. Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia. Int J Antimicrob Agents 2010; 36(4): 384-5.
27. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010; 16(2): 78-86.
28. Dumke R, von Baum H, Luck PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010; 6(6): 613-6.
29. Cao B, Zhao CJ, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 2010; 51(2): 189-94.
30. van der Linden M, Al-Lahham A, Haupts S, Reinert RR. Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany. Antimicrob Agents Chemother 2007; 51(5): 1830-4.
31. Degrange S, Cazanave C, Charron A, et al. Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of Mycoplasma pneumoniae. J Clin Microbiol 2009; 47(4): 914-23.
32. Morozumi M, Hasegawa K, Kobayashi R, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother 2005; 49(6): 2302-6.
33. Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolideresistant strains from Shanghai, China. Antimicrob Agents Chemother 2009; 53(5): 2160-2.
34. Okazaki N, Ohya H, Sasaki T. Mycoplasma pneumoniae isolated from patients with respiratory infection in Kanagawa Prefecture in 1976-2006: emergence of macrolide-resistant strains. Jpn J Infect Dis 2007; 60(5): 325-6.
35. Matsubara K, Morozumi M, Okada T, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 2009; 15(6): 380-3.
36. Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008; 52(1): 348-50.
37. Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolideresistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012; 17(2): 354-62.
38. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol 2007; 45(11): 3534-9.
39. Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011; 66(4): 734-7.
40. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011; 17(6): 1079-82.
41. Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the Central United States. Pediatr Infect Dis J 2012; 31(4): 409-10.
42. Lu YJ, Chen TH, Lin LH, Shen CM, Huang CH. Macrolide use shortens fever duration in Mycoplasma pneumoniae infection in children: a 2-year experience. J Microbiol Immunol Infect 2008; 41(4): 307-10.
43. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292(1): 156-63.
44. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14(6): 471-7.
45. Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17(10): 865-71.
46. Hyde TB, Gilbert M, Schwartz SB, et al. Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia. J Infect Dis 2001; 183(6): 907-12.
47. Klausner JD, Passaro D, Rosenberg J, et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis 1998; 177(1): 161-6.
48. Atkinson TP, Boppana S, Theos A, et al. Stevens-Johnson syndrome in a boy with macrolide-resistant Mycoplasma pneumoniae Pneumonia. Pediatrics 2011; 127(6): e1605-9.
49. Cardinale F, Chironna M, Dumke R, et al. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J 2011; 37(6): 1522-4.
50. To KK, Chan KH, Fung YF, Yuen KY, Ho PL. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. Eur Respir J 2010; 36(4): 969-71.
51. Miyashita N, Maruyama T, Kobayashi T, et al. Communityacquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother 2011; 17(1): 114-8.
52. Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006; 50(2): 709-12.
53. Narita M. Two unexpected phenomena in macrolide-resistant Mycoplasma pneumoniae infection in Japan and the unique biological characteristics of Mycoplasma pneumoniae. J Infect Chemother 2011; 17(5): 735-6.
54. Sendi P, Graber P, Lepere F, Schiller P, Zimmerli W. Mycoplasma pneumoniae infection complicated by severe mucocutaneous lesions. Lancet Infect Dis 2008; 8(4):268.